Provention Bio (PRVB) Releases Earnings Results

Provention Bio (NASDAQ:PRVB) announced its earnings results on Thursday. The company reported ($0.17) earnings per share (EPS) for the quarter, Morningstar.com reports.

Shares of Provention Bio stock traded down $0.02 on Friday, reaching $3.16. 21,053 shares of the company were exchanged, compared to its average volume of 51,935. Provention Bio has a fifty-two week low of $2.52 and a fifty-two week high of $8.00.

An institutional investor recently bought a new position in Provention Bio stock. Dean Capital Investments Management LLC bought a new position in shares of Provention Bio Inc (NASDAQ:PRVB) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 40,950 shares of the company’s stock, valued at approximately $164,000. Dean Capital Investments Management LLC owned 0.12% of Provention Bio as of its most recent SEC filing.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/11/10/provention-bio-prvb-releases-earnings-results.html.

Provention Bio Company Profile

Provention Bio, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D.

Further Reading: Asset Allocation, Balancing Your Investments

Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply